Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.
Musella M, Guarracino A, Manduca N, Galassi C, Ruggiero E, Potenza A, Maccafeo E, Manic G, Mattiello L, Soliman Abdel Rehim S, Signore M, Pietrosanto M, Helmer-Citterich M, Pallocca M, Fanciulli M, Bruno T, De Nicola F, Corleone G, Di Benedetto A, Ercolani C, Pescarmona E, Pizzuti L, Guidi F, Sperati F, Vitale S, Macchia D, Spada M, Schiavoni G, Mattei F, De Ninno A, Businaro L, Lucarini V, Bracci L, Aricò E, Ziccheddu G, Facchiano F, Rossi S, Sanchez M, Boe A, Biffoni M, De Maria R, Vitale I, Sistigu A. Musella M, et al. Among authors: di benedetto a. Nat Immunol. 2022 Sep;23(9):1379-1392. doi: 10.1038/s41590-022-01290-3. Epub 2022 Aug 24. Nat Immunol. 2022. PMID: 36002648 Free PMC article.
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.
Fabi A, Di Benedetto A, Metro G, Perracchio L, Nisticò C, Di Filippo F, Ercolani C, Ferretti G, Melucci E, Buglioni S, Sperduti I, Papaldo P, Cognetti F, Mottolese M. Fabi A, et al. Among authors: di benedetto a, di filippo f. Clin Cancer Res. 2011 Apr 1;17(7):2055-64. doi: 10.1158/1078-0432.CCR-10-1920. Epub 2011 Feb 9. Clin Cancer Res. 2011. PMID: 21307144
Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.
Fabi A, Merola R, Ferretti G, Di Benedetto A, Antoniani B, Ercolani C, Nisticò C, Papaldo P, Ciccarese M, Sperduti I, Vici P, Marino M, Gori S, Botti C, Malaguti P, Cognetti F, Mottolese M. Fabi A, et al. Among authors: di benedetto a. Expert Opin Pharmacother. 2013 Apr;14(6):699-706. doi: 10.1517/14656566.2013.779672. Epub 2013 Mar 9. Expert Opin Pharmacother. 2013. PMID: 23472669
p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab.
Vici P, Sperati F, Maugeri-Saccà M, Melucci E, Di Benedetto A, Di Lauro L, Pizzuti L, Sergi D, Terrenato I, Esposito L, Iannuzzi CA, Pasquale R, Botti C, Fuhrman B, Giordano A, Mottolese M, Barba M. Vici P, et al. Among authors: di benedetto a, di lauro l. Oncotarget. 2014 Nov 15;5(21):10382-92. doi: 10.18632/oncotarget.2060. Oncotarget. 2014. PMID: 25071015 Free PMC article.
Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series.
Di Lauro L, Vici P, Barba M, Pizzuti L, Sergi D, Rinaldi M, Di Benedetto A, Sperduti I, Shaaban AM, Speirs V, Mottolese M, De Maria R, Maugeri-Saccà M. Di Lauro L, et al. Among authors: di benedetto a. Breast Cancer Res Treat. 2014 Nov;148(1):73-80. doi: 10.1007/s10549-014-3138-9. Epub 2014 Sep 20. Breast Cancer Res Treat. 2014. PMID: 25238881
The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.
Vici P, Mottolese M, Pizzuti L, Barba M, Sperati F, Terrenato I, Di Benedetto A, Natoli C, Gamucci T, Angelucci D, Ramieri MT, Di Lauro L, Sergi D, Bartucci M, Dattilo R, Pagliuca A, De Maria R, Maugeri-Saccà M. Vici P, et al. Among authors: di benedetto a, di lauro l. Oncotarget. 2014 Oct 30;5(20):9619-25. doi: 10.18632/oncotarget.2449. Oncotarget. 2014. PMID: 25294813 Free PMC article. Clinical Trial.
ATM kinase sustains HER2 tumorigenicity in breast cancer.
Stagni V, Manni I, Oropallo V, Mottolese M, Di Benedetto A, Piaggio G, Falcioni R, Giaccari D, Di Carlo S, Sperati F, Cencioni MT, Barilà D. Stagni V, et al. Among authors: di carlo s, di benedetto a. Nat Commun. 2015 Apr 16;6:6886. doi: 10.1038/ncomms7886. Nat Commun. 2015. PMID: 25881002 Free article.
Androgen receptor and antiandrogen therapy in male breast cancer.
Di Lauro L, Barba M, Pizzuti L, Vici P, Sergi D, Di Benedetto A, Mottolese M, Speirs V, Santini D, De Maria R, Maugeri-Saccà M. Di Lauro L, et al. Among authors: di benedetto a. Cancer Lett. 2015 Nov 1;368(1):20-25. doi: 10.1016/j.canlet.2015.07.040. Epub 2015 Aug 11. Cancer Lett. 2015. PMID: 26276719 Free article. Review.
Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis.
Vici P, Di Benedetto A, Ercolani C, Pizzuti L, Di Lauro L, Sergi D, Sperati F, Terrenato I, Dattilo R, Botti C, Fabi A, Ramieri MT, Mentuccia L, Marinelli C, Iezzi L, Gamucci T, Natoli C, Vitale I, Barba M, Mottolese M, De Maria R, Maugeri-Saccà M. Vici P, et al. Among authors: di benedetto a, di lauro l. Oncotarget. 2015 Dec 15;6(40):42773-80. doi: 10.18632/oncotarget.6001. Oncotarget. 2015. PMID: 26544894 Free PMC article.
Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Vici P, Ercolani C, Di Benedetto A, Pizzuti L, Di Lauro L, Sperati F, Terrenato I, Gamucci T, Natoli C, Di Filippo F, Botti C, Barba M, Mottolese M, De Maria R, Maugeri-Saccà M. Vici P, et al. Among authors: di benedetto a, di filippo f, di lauro l. J Exp Clin Cancer Res. 2016 Apr 2;35:62. doi: 10.1186/s13046-016-0338-7. J Exp Clin Cancer Res. 2016. PMID: 27039292 Free PMC article.
470 results